We aimed to assess the effects of rosuvastatin treatment on lipid levels, a biomarker of oxidative stress, albuminuria, and kidney function in patients with diabetic nephropathy. Methods: We conducted a prospective, open-label, parallel group, controlled study of 104 patients with diabetic nephropathy, low-density lipoprotein cholesterol (LDL-C) levels of 120 mg/dL, and well-controlled blood pressure who were undergoing treatment with renin angiotensin system inhibitors. Patients were randomly assigned to two groups: the rosuvastatin group (n 52; 2.5 mg/day rosuvastatin, increased to 10 mg/day) and the control group (n 52; no rosuvastatin administered). We determined the efficacy of rosuvastatin by monitoring serum lipid profiles, high sensitivity C-reactive protein (hs-CRP), malondialdehyde-modified LDL (MDA-LDL), and cystatin C levels. In addition, urinary albumin, 8-hydroxydeoxyguanosine (8-OHdG) and liver-type fatty acid-binding protein (L-FABP) levels were measured before and 6 months after rosuvastatin was added to the treatment. Results: Rosuvastatin effectively reduced total cholesterol, LDL-C, triglycerides, non-high-density lipoprotein cholesterol (non-HDL-C) levels, and the LDL-C/ HDL-C ratio in the rosuvastatin group. These parameters remained unchanged in patients who were not treated with rosuvastatin. Although there was no significant change in the estimated glomerular filtration rate level, serum cystatin C levels and urinary albumin excretion rates were significantly decreased in the rosuvastatin group. In addition, rosuvastatin significantly reduced hs-CRP and MDA-LDL levels. Moreover, urinary 8-OHdG and L-FABP levels at baseline (13.5 5.1 and 41.7 26.1 ng/mgCr, respectively) decreased significantly at 6 months (11.5 4.0 and 26.9 13.4 ng/mgCr, respectively), and there was a significant correlation (r 0.48, p 0.01). Multivariate analysis revealed that albuminuria was significantly correlated with only rosuvastatin use (p 0.0006, R 2 0.53). Conclusion: Rosuvastatin administration reduced albuminuria, oxidative stress, and serum cystatin C levels, independent of blood pressure and lipid levels.
cardiovascular disease (CVD) 5, 6) . Hyperlipidemia may play an important role in the progression of chronic kidney disease (CKD) including diabetic nephropathy through either the toxic effects of lipids on mesangial cells or by promoting intrarenal atherosclerosis [7] [8] [9] . Although the pathogenesis of diabetic nephropathy is multifactorial and the precise mechanisms of its action are unclear, the rate of functional deterioration correlates with the degree of renal tubulointerstitial fibrosis 10) . Diabetic hyperglycemia is associated with increased production of reactive oxygen species (ROS). ROS damage to DNA necessitates the induction of various DNA repair processes, which can result in the urinary excretion of products such as 8-hydroxydeoxyguanosine . Urinary 8-OHdG is therefore a sensitive biomarker of oxidative DNA damage, and also correlates significantly with the severity of tubulointerstitial lesions 11) . Furthermore, the liver-type fatty acid-binding protein (L-FABP) is expressed in proximal tubules. L-FABP plays a key role in fatty acid metabolism in proximal tubules, and its expression is induced by fatty acids 12) . Tubulointerstitial inflammation induced by lipid toxicity might be provoked by not only proteinuria but also other stressors. Various stressors to proximal tubules overload fatty acids in the cytoplasm and thereby damage the tubules by releasing inflammatory factors, and such tubulointerstitial inflammation deteriorates renal function over time; therefore, oxidative stress may contribute to the progression of tubulointerstitial injury in patients with diabetic nephropathy 11, 12) .
In addition to lipid-lowering effects, statins, a type of HMG-CoA reductase inhibitor, exert numerous cardioprotective effects by increasing the bioavailability of vascular nitric oxide (NO) and reducing oxidative stress and inflammatory cytokines [13] [14] [15] . Among the statins available as medication, rosuvastatin is considered to have robust effects, including highly effective lowering of low-density lipoprotein cholesterol (LDL-C), significant raising of high-density lipoprotein cholesterol (HDL-C), lowering of high-sensitivity C-reactive protein (hs-CRP), and stabilizing of risk factors and biomarkers of atherosclerosis both clinically and in experimental animal models 16, 17) ; however, little is known about the renal protective effects of rosuvastatin for regulation of urinary oxidative stress markers and albuminuria in patients with diabetic nephropathy. Furthermore, no studies have reported additional therapy for further reduction of albuminuria if blood pressure has been well controlled by RAS inhibitors. It remains unknown, therefore, whether a ceiling of renoprotection exists, provided by RAS inhibitors. Thus, we investigated whether the add-on effect of rosuvastatin was effective for reducing albuminuria when given to diabetic patients with wellcontrolled hypertension who were already undergoing treatment with RAS inhibitors, and whether renoprotection is mediated by inhibiting oxidative stress in the kidney.
Methods

Patients and Study Design
This study was conducted as a prospective, randomized, and open-labeled clinical trial over 6 months. Enrollment criteria for the patients entailed: 1) type 2 diabetes mellitus in those who were not treated with statins within 6 months of the start of the trial 2) LDL-C ≥ 120 mg/dL; 3) stage 1-2 CKD, as indicated by an estimated glomerular filtration rate (eGFR) of ≥ 60 mL/min/1.73 m 2 ; 4) albuminuria, i.e., urinary albumin/creatinine (Cr) ratio of ≥ 30 mg/g (average of 2 consecutive measurements taken during a 4-week period before the study); and 5) BP 140/90 mmHg treated with RAS inhibitors including ACE inhibitors and/or ARBs for at least 8 weeks before the study.
Exclusion criteria were as follows: 1) age 20 years or 80 years; 2) eGFR 60 mL/min/1.73 m 2 ; 3) BP ≥ 140/90 mmHg; 4) history of heart failure, angina, myocardial infarction, or stroke within 6 months before the start of the trial; 5) previous treatment with steroids or immunosuppressants; or 6) diabetes mellitus that led to hospitalization because of diabetic ketoacidosis.
We designed this study to assess the effect of rosuvastatin in patients with diabetic nephropathy. After initial evaluation, we randomly assigned 52 patients to add-on therapy with rosuvastatin (rosuvastatin group), while 52 patients continued with conventional therapy as controls (control group) consecutively. A computer-generated list was used for randomization. Patients in the rosuvastatin group started with 2.5 mg rosuvastatin once daily. This dose was increased to 10 mg daily if target LDL-C levels ( 100 mg/dL) were not reached after 4 weeks. These subjects were already being administered RAS inhibitors and were controlled to ensure BP 140/90 mmHg. The investigators subjectively adjusted the dose of antidiabetic agents such that the level of glycated hemoglobin (HbA1c), a glycemic target, achieved 7.0% in both groups. We obtained written informed consent for participation in the trial from all patients, and the protocol of the trial was approved by the ethics committee of our institution. In addition, the study was conducted in accordance with the Declaration of Hel-sinki. This prospective study was conducted between December 2009 and December 2010, and the subjects were followed for 6 months. Doses of ARBs and ACEIs were not altered during the study period. All patients were instructed on how to maintain their diet and exercise therapy. Furthermore, all patients received nutrition education from a dietitian according to the Impact of the Kidney Disease Outcomes Quality Initiative guideline 18) .
Laboratory Analysis
The glomerular filtration rate (GFR) was estimated using the final recommended modified equation for Japanese patients of the Japanese Society of Nephrology-Chronic Kidney Disease Initiatives because the eGFR obtained by this method is more accurate for application in Japanese patients with CKD than values obtained using other equations 19) . The eGFR was calculated according to the following formula: eGFR (mL/min/1.73 m 2 ) 194 sCr 1.094 Age 0.287 (0.739 in the case of women).
Fasting blood samples were obtained from all subjects, and HbA1c and plasma glucose were measured as criteria for glycemic control. Hemoglobin, total bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, -glutamyl transpeptidase, creatine phosphokinase (CK), total cholesterol (TC), HDL-C, and triglycerides (TG) were routinely measured following clinical chemistry procedures using commercial kits. The serum concentration of LDL-C was estimated using the Friedewald formula (LDL-C TC HDL-C TG 0.2) in patients with serum TG concentrations of 400 mg/dL. The percent changes of serum TC, LDL-C, TG, HDL-C, non-HDL-C, and LDL-C/HDL-C were calculated in all patients. Serum malondialdehyde-modified LDL (MDA-LDL) was assayed by enzyme-linked immunosorbent assay (ELISA) as described previously 20) . Serum cystatin C was measured by the fully automated sol particle immunoassay method described previously (Alfresa Pharma Co., Osaka, Japan) 21) , and hs-CRP was measured by latex agglutination. Urinary 8-OHdG levels were measured with an ELISA kit that employs a highly sensitive monoclonal antibody in the first morning urine sample, as previously described (8-OHdG Check; Japan Institute for the Control of Aging, Shizuoka, Japan) 22) . Similarly, urinary L-FABP was measured with an ELISA kit that uses human monoclonal antibodies, as described previously (CMIC Co. Ltd., Tokyo, Japan) 12) . These results were adjusted for Cr (ng/mgCr) measured using the same urine sample. Urinary albumin excretion was assessed by mea-suring urinary concentrations of albumin and creatinine (albumin/Cr ratio) in the first morning urine sample. Urinary albumin was measured using the immunoturbidimetry method.
Safety Variables
At each visit, patients were questioned about compliance (diet and medication), concomitant medication, and adverse events. Safety assessments were performed repeatedly throughout the study. Adverse events were graded on the basis of intensity (mild, moderate, or severe). Serious adverse events were defined as significant and untoward medical events that resulted in death, hospitalization, or significant disability or incapacity. Patient withdrawal from the study was considered if allergy or intolerance to rosuvastatin appeared during the study, a hypertensive emergency developed, or if either serum CK or transaminase concentration increased 2-fold the upper limit of the normal range and the patient concomitantly exhibited symptoms such as muscular pain, loss of appetite, or general fatigue, or if the patient was subjected to any other condition or therapy that, in the opinion of the investigators, might have posed a risk to the patient or confounded the results of the study.
Statistical Analysis
Results are expressed as the mean SD. Because many variables did not show a normal distribution, non-parametric statistical tests were used throughout. The unpaired t -test or Mann-Whitney U -test was used to compare the mean baseline data values between the groups. Intra-group comparisons were assessed by the Wilcoxon signed rank test or paired t -test. Changes in parameters at baseline and at 24 weeks were compared using analysis of variance with repeated measurements, followed by a subsequent multiple comparison test. Relationships between the changes were studied using Pearson's correlation and multiple linear regression analysis. Statistical significance was established at p 0.05. The SAS 8.13 statistical package (SAS Institute, Cary, NC, USA) was utilized for all analyses.
Results
Baseline Characteristics
We enrolled 104 subjects for this study and randomly allocated them to the rosuvastatin group (n 52) or control group (n 52). The baseline characteristics and medications administered to the subjects in the 2 groups are shown in Table 1 . No significant differences were observed between the 2 groups with regard to the baseline characteristics or medications. The dosage of antidiabetic agents did not differ between the two groups. Although the mean body mass index of all patients was 22.8 2.6 kg/m 2 and baseline BP was well controlled, adequate LDL-C control had not been achieved in any of the enrolled patients. During treatment, one subject from the rosuvastatin group withdrew from the study due to an adverse reaction, and 2 subjects from the control group withdrew due to congestive heart failure and alteration of antihypertensive agents due to an increase in BP; therefore, 51 patients in the rosuvastatin group and 50 patients in the control group completed the trial and were analyzed.
Changes in BP and Glycemic Control
As shown in Table 2 , there were no significant changes in BP or heart rate between the groups at baseline and throughout the study period. Further- more, there was no significant change in HbA1c or fasting plasma glucose levels between the two groups, and therefore, no patients were subjected to additional anti-diabetic agents.
Lipid Profiles
The mean dosage of rosuvastatin at the end of the study was 3.1 1.0 mg daily (2.5 mg daily, n 40; 5.0 mg daily, n 9; 10 mg daily, n 2). TC, LDL-C, HDL-C, non-HDL-C, TG, and LDL-C/HDL-C ratios at baseline and after 6 months are shown in Table 3 . There were no significant changes in TC LDL-C, HDL-C, non-HDL-C, TG, and LDL-C/ HDL-C in the control group. On the other hand, TC and LDL-C after administration of rosuvastatin fell from 227 23 mg/dL to 172 28 mg/dL and from 137 19 mg/dL to 83 16 mg/dL, respectively (both p 0.0001). HDL-C after administration of rosuvastatin increased from 49 10 mg/dL to 53 15 mg/dL (p 0.05), while non-HDL-C fell from 177 25 mg/dL to 118 26 mg/dL (p 0.0001). LDL-C/ HDL-C ratios and TG after administration of rosuvastatin decreased from 2.8 0.7 to 1.6 0.5 (p 0.0001) and from 162 81 to 130 ± 66 mg/dL (p 0.0001), respectively.
Kidney Function
As shown in Fig. 1 , there was a significant increase in sCr levels in the control group (from 0.78 0.12 to 0.79 0.13 mg/dL, p 0.05), whereas there was no significant change in sCr levels in the rosuvastatin group during the treatment period (from 0.78 0.16 mg/dL to 0.78 0.15 mg/dL).
Similarly to sCr levels, there was a significant decrease in eGFR in the control group from baseline to the end of the study (from 69.3 9.5 to 68.4 10.0 mL/min/1.73 m 2 , p 0.05), whereas there was no significant change in eGFR in the rosuvastatin group from baseline to the end of the study (from 70.4 11.9 to 70.0 11.8 mL/min/1.73 m 2 ). On the other hand, serum cystatin C in the rosuvastatin group significantly decreased from 0.80 0.13 to 0.76 0.13 mg/L (p 0.0001), whereas a significant increase was observed in the control group from 0.80 0.11 to 0.81 0.12 (p 0.05). As shown in Fig. 2 , there was no significant change in the urinary albumin/Cr ratio in the control group (from 142 83 to 141 72 mg/gCr), whereas the urinary albumin/Cr ratio significantly decreased in the rosuvastatin group (from 141 86 mg/gCr to 82 54 mg/gCr) (p 0.01). Percent changes from baseline values significantly decreased in the rosuvastatin 
hs-CRP and MDA-LDL
As shown in Fig. 3 , there was no significant change in hs-CRP in the control group (from 1.31 0.82 to 1.32 0.81), whereas hs-CRP in the rosuvastatin group significantly decreased (from 1.38 0.80 to 0.71 0.70 mg/L) (p 0.0001). There was also no significant change in MDA-LDL in the control group, whereas there was a significant reduction in MDA-LDL in the rosuvastatin group (from 156 42 to 94 28 U/L; p 0.0001). MDA-LDL was decreased by 40% in the rosuvastatin group compared with baseline values.
Urinary 8-OHdG and L-FABP
As shown in Fig. 4 , urinary 8-OHdG levels were significantly decreased in the rosuvastatin group (from 13.5 5.1 to 11.5 4.0 ng/mgCr, p 0.001), and there was a significant difference compared with the control group at the end of the study (11. 
Correlation
To identify the determinants of a decrease in urinary albumin excretion, multivariate analysis was performed ( Table 4) . Multivariate regression analysis with percent reduction of albuminuria as the dependent variable and age, sex, change in mean blood pressure, lipid profiles, and the presence or absence of rosuvastatin as independent variables was performed to investigate the effect of rosuvastatin and other risk factors on albuminuria. The results revealed that the use of rosuvastatin was the only factor that was significantly related to albuminuria regression (p 0.0006, R 2 0.53). Table 5 shows the correlations among the monitored parameters in the rosuvastatin group. Although there were significant correlations between the lipid parameters, such as changes in TC, LDL-C, non-HDL-C, LDL/HDL-C, and MDA-LDL, a weak correlation was observed between the change in albuminuria and that of MDA-LDL following rosuvastatin treatment (r 0.277; p 0.041). Although the percent change in the albumin/Cr ratio from baseline to the end of the study did not correlate with the percent change in urinary 8-OHdG and L-FABP in the rosuvastatin group, the change in urinary 8-OHdG was significantly correlated with the change in L-FABP (r 0.48, p 0.0003). Furthermore, multivariate analysis was performed to identify the lipids or oxidative stress factors that decrease albuminuria. Multivariate regression analysis with percent change in albuminuria as the dependent variable and change in lipid profiles, MDA-LDL, and hs-CRP as independent variables was performed to investigate the effect of rosuvastatin on albuminuria. The results revealed that no factor was significantly related to albuminuria regression after rosuvastatin treatment. Additionally, no significant correlation was observed between the change in albuminuria and hemodynamics (systolic and diastolic blood pressure; data not shown).
Although the dose of rosuvastatin was significantly correlated with the percent decrease of TC, LDL, non-HDL, LDL-C/HDL-C, and MDA-LDL, there was no significant relationship with the change in albuminuria, urinary 8-OHdG, and L-FABP. 
Safety
During treatment, adverse reactions were observed in 1 subject from the rosuvastatin group, and administration of rosuvastatin was discontinued in this individual. This subject had muscular pain, which was considered to be attributed to rosuvastatin, and was relieved by discontinuation of rosuvastatin treatment; however, no elevated CK was observed in this subject. In 1 patient from each group, the dose of antidiabetic agents was increased due to increasing HbA1c during the study period. In the same 2 patients, the dose of dipeptidyl peptidase-4 inhibitor was also increased. On the other hand, none of the patients had a hypoglycemic episode or decreased the dose of antidiabetic agents.
Discussion
In the present study, rosuvastatin significantly improved LDL-C, non-HDL-C, and HDL-C, as well as the LDL-C/HDL-C ratio in patients with diabetic nephropathy when compared with the values at baseline and in the control group. Rosuvastatin reduces both albuminuria and the rate of progression of kidney disease in patients with diabetic nephropathy, and the benefits appear to supplement those derived from treatment with RAS inhibitors. In the present study, MDA-LDL was significantly decreased by rosuvastatin treatment. Furthermore, despite the fact that there were no significant correlations between the reduction of albuminuria and other lipid parameters, the change in MDA-LDL was significantly correlated with the reduction of albuminuria in this analysis, although the correlation coefficient was small; therefore, it is possible that the decrease in MDA-LDL can be attributed to the reduction of albuminuria. A reduction in the serum concentration of MDA-LDL, which is a major component of oxidized LDLs, may reduce not only the likelihood of future atherosclerotic disease and cardiovascular events, but also the progression of kidney disease.
The pathogenesis of diabetic nephropathy is multifactorial and its precise mechanisms of action remain unclear; however, it is now widely accepted that the rate of functional deterioration correlates with the degree of renal tubulointerstitial fibrosis 10) . Epithelial cells of the proximal tubules play a major role in orchestrating events in the renal interstitium in diabetic nephropathy 23) . In addition, oxidative stress may contribute to the progression of tubulointerstitial injury in patients with diabetic nephropathy 11) . In the present study, we showed that rosuvastatin reduced not only hs-CRP levels and MDA-LDL, but also urinary 8-OHdG and L-FABP levels; therefore, the beneficial effect of rosuvastatin in diabetic nephropathy might be mediated by the systemic oxidative stressameliorating effect, which is pleiotropic and regulates anti-inflammatory reduction. The antioxidant effects of statins likely contribute to their clinical efficacy in treating cardiovascular diseases as well as other chronic conditions associated with increased oxidative stress in humans. Rosuvastatin is effective in protecting against tubulointerstitial injury and in reducing oxidative stress in diabetic patients with CKD; however, further long-term studies are needed for more precise evaluation of the effects of rosuvastatin on albuminuria and kidney function. In a sub-analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, concomitant decreases in eGFR and creatinine clearance were observed following fenofibrate administration, but no beneficial effects on albuminuria were noted 24) . On the other hand, meta-regression analysis showed that statins reduced cardiovascular events in patients with CKD at a rate similar to that seen in the general population, and treatment effects did not vary significantly with various stages of CKD, namely, the predialysis, dialysis, and transplant populations 25) . Statin therapy resulted in a small reduction in the rate of kidney function loss in subjects with CVD but was not significant in subjects with diabetic or hypertensive kidney disease or glomerulonephritis when compared to a placebo 26) . Furthermore, statins seemed to reduce proteinuria and albuminuria when compared to a placebo 27) ; however, the antiproteinuric effect of rosuvastatin in patients with diabetic nephropathy has not been clarified because the meta-analyses in the above studies were based on investigations using simvastatin or pravastatin treatment for subjects with CVD who were not limited to diabetics. In the present study, rosuvastatin treatment reduced albuminuria significantly in diabetic patients. On the other hand, statins did not improve GFR, but significantly reduced proteinuria and albuminuria 25) . In a sub-analysis of the Treating to New Targets (TNT) study, treatment with 10 mg and 80 mg atorvastatin was found to increase eGFR by 3.5 mL/min/1.73 m 2 and 5.2 mL/min/1.73 m 2 , respectively 28) . In contrast, in the Prevention of Renal and Vascular End-stage Disease Intervention trial (PREVEND-IT), treatment with 40 mg pravastatin did not result in any changes in eGFR 29) . Thus, the beneficial effect of statins on eGFR in diabetic nephropathy remains controversial. On the other hand, comparing the serum Cr with conventional estimates, based on serum cystatin C measurements for detecting very early reduction of kidney function, can be useful for measuring kidney function and will optimize early detection, prevention, and treatment strategies for diabetic nephropathy 30, 31) . Furthermore, cystatin C is a potent predictor of cardiovascular mortality beyond classical factors in patients with coronary artery disease and normal or mildly reduced kidney function 32) . In the present study, although the degree was small, eGFR decreased in the control group. On the other hand, there was no significant difference in eGFR in the rosuvastatin group; in other words, eGFR could be maintained in the rosuvastatin group without decreasing. This finding was expected because the present study period was relatively short; however, the results revealed that cystatin C, which is a more sensitive marker of changes in GFR, is significantly reduced by rosuvastatin treatment.
In conclusion, the present study demonstrated that rosuvastatin administration reduced urinary albumin excretion, urinary 8-OHdG, and L-FABP in patients with diabetic nephropathy and well-controlled hypertension, independent of blood pressure and lipid changes. This was achieved in part due to reducing oxidative stress; however, the precise mechanisms remain unclear. Rosuvastatin may ameliorate the progression of tubulointerstitial lesions in diabetic nephropathy. Furthermore, rosuvastatin treatment resulted in a significant decrease of cystatin C after 24 weeks, suggesting that rosuvastatin might maintain the GFR as well as contribute to a reduction in the risk of CVD in patients with diabetic nephropathy. Further prospective long-term clinical trials are needed for a more precise evaluation of the effects of rosuvastatin on renal outcome.
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